ask why
Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

The papers that matter: 1 December to 7 December 2025

The 10 most important of the 145 papers published that week and summarised on Y, ranked by what verified readers said would change practice, then by strength of design and size. Secondary analyses come last.
Oncology · Lancet Oncol · 2025-12-01

Pooled individual-patient analysis of 11 neoadjuvant early breast cancer RCTs (12,247 patients): distant disease-free survival was a strong trial-level surrogate for overall survival (R2trial 0.91), but weak in hormone receptor-positive subtypes.

Meta-analysisn = 12,247
Conforti et al. Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials

Previous weekNext weekAll weeks

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.